BOULDER, Colo., Dec. 3, 2025 /PRNewswire/ — Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection technology, today announced the presentation of multiple lymphoma studies featuring Foresight CLARITY™ (PhasED-Seq) minimal residual disease (MRD) analysis at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6–9, 2025, in Orlando, Florida.

This year’s presentations reflect the growing integration of highly sensitive, circulating tumor DNA (ctDNA)-based MRD testing into clinical studies across hematologic malignancies. Academic groups and pharmaceutical partners are increasingly deploying MRD not only for retrospective assessment but also prospectively within MRD-guided trial designs, exploratory endpoints, and therapeutic development programs.

“Across industry and academic collaborators, we’re seeing a meaningful shift in how ctDNA-MRD is being used in lymphoma,” said David Kurtz, MD, PhD, Chief Medical Officer and Co-founder of Foresight Diagnostics. “Ultrasensitive MRD analysis is moving beyond feasibility studies and into clinical trial frameworks, where molecular response has the opportunity to inform patient care decisions. At Foresight Diagnostics, we’re proud to support this next phase of MRD-driven innovation in lymphoma.”

Information on presentations and posters featuring Foresight CLARITY (PhasED-Seq™) MRD analysis can be found below. To meet with Foresight Diagnostics, visit booth #2165 or contact us at [email protected].

Saturday, December 6

Response-adapted Phase 2 study of acalabrutinib window prior to frontline chemotherapy in untreated large B-cell lymphoma: Molecular correlates of response to acalabrutinib | Mark Roschewski, MD (NCI/NIH) | 9:45-10:00 AM EST | Oral presentation
First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctDNA analysis from dose escalation | Swetha Thiruvengadam, MD (City of Hope) | 1:00-1:15 PM EST | Oral presentation
Spatial anatomical genomic heterogeneity and aberrant somatic hypermutation define clonal evolution pathways that predict treatment resistance in aggressive B-cell lymphomas | Jordan Goldstein, MD, MSc (Stanford University) | 5:15-5:30 PM EST | Oral presentation

Sunday, December 7

Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, plus R-CHOP in patients (Pts) with previously untreated aggressive B-cell lymphoma (a-BCL): 24-month efficacy results | Grzegorz Nowakowski, MD (Bristol Myers Squibb) | 9:45-10:00 AM EST | Oral presentation
Primary analysis of the SMART STOP trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma | Jason Westin, MD (MD Anderson Cancer Center) | 10:00-10:15 AM EST | Oral presentation
Longitudinal circulating tumor DNA dynamics during & after first-line therapy in a national cohort of large B-cell lymphomas | Steven Wang, MD (Stanford University; formerly UMC Amsterdam) | 10:45-11:00 AM EST | Oral presentation
Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis | Ryan Lynch, MD (Fred Hutch/University of Washington) | 6:00-8:00 PM EST | Poster
Pembrolizumab + GVD with ctDNA-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium | Michael Randall, MD (UCSF) | 6:00-8:00 PM EST | Poster
First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open label Phase 2 ALPHA3 study | John M. Burke, MD (Rocky Mountain Cancer Centers) | 6:00-8:00 PM EST | Poster
Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, + R-CHOP vs placebo + R-CHOP in patients with previously untreated, high-risk, large B-cell lymphoma | Jason Westin, MD (MD Anderson Cancer Center) | 6:00-8:00 PM EST | Poster

Monday, December 8

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctDNA evaluation in advanced Hodgkin lymphoma | Ryan Lynch, MD (Fred Hutch/University of Washington) | 6:00-8:00 PM EST | Poster

About Foresight Diagnostics

Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on X, LinkedIn, and Bluesky.

View original content to download multimedia:https://www.prnewswire.com/news-releases/foresight-diagnostics-announces-multiple-presentations-in-lymphoma-featuring-phased-seq-ultrasensitive-mrd-analysis-at-the-upcoming-ash-annual-meeting-302631204.html